BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15761510)

  • 21. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
    Kloos RT
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5241-8. PubMed ID: 20843945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study.
    Rosario PW; dos Santos JB; Calsolari MR
    Horm Metab Res; 2013 Nov; 45(12):911-4. PubMed ID: 23757117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
    Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
    Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
    Toubeau M; Touzery C; Arveux P; Chaplain G; Vaillant G; Berriolo A; Riedinger JM; Boichot C; Cochet A; Brunotte F
    J Nucl Med; 2004 Jun; 45(6):988-94. PubMed ID: 15181134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?
    Ibrahimpasic T; Ghossein R; Carlson DL; Nixon IJ; Palmer FL; Patel SG; Tuttle RM; Shaha A; Shah JP; Ganly I
    Ann Surg Oncol; 2015 Dec; 22(13):4193-7. PubMed ID: 25893415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
    Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
    Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V; Nayer PD; Bouckaert A; Beckers C
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer.
    Zhang HS; Wang RJ; Fu QF; Gao S; Sun BT; Sun H; Ma QJ
    Asian Pac J Cancer Prev; 2014; 15(24):10905-9. PubMed ID: 25605199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.